PA
CLB icon

PharVision Advisers’s Core Laboratories CLB Stock Holding History

PharVision Advisers’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,676
Closed -$218K – 730
2025
Q3 		$218K Buy
+17,676
New +$207K 0.12% 434

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PharVision Advisers's CLB Position: Q4 2025 in Review

PharVision Advisers sold out of Core Laboratories (CLB) in Q4 2025, closing a stake of 17,676 shares — an estimated $218K sold.

PharVision Advisers first reported a position in CLB in Q3 2025 and held it in 1 quarter. The position peaked at $218K in Q3 2025. 187 funds tracked by Wall St. Rank hold CLB as of Q4 2025.

  • PharVision Advisers reported no remaining Core Laboratories position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 17,676 Core Laboratories shares in Q4 2025, an estimated $218K.
  • PharVision Advisers first reported a position in Core Laboratories in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Core Laboratories position peaked at $218K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.